Sanofi-Synthelabo Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Sanofi-Synthelabo, a foreign private issuer headquartered in Paris, France, on November 13, 2002. The filing covers the month of November 2002 and serves to communicate the estimated schedule for key financial announcements for the upcoming 2003 fiscal year.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is purely informational regarding future reporting dates and contains no financial performance data for the current or prior periods.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document does not contain comparative data against prior periods.
Guidance, Outlook, and Management Commentary
Management has provided a schedule of anticipated financial disclosures for 2003. The estimated dates for key announcements are as follows:
- January 22, 2003: 2002 sales press release.
- February 18, 2003: 2002 results press release.
- April 24, 2003: 1st quarter 2003 sales press release.
- May 19, 2003: Shareholders General Meeting.
- July 23, 2003: 1st half 2003 sales press release.
- September 2, 2003: 1st half 2003 results press release.
- October 22, 2003: 9 months 2003 sales press release.
The filing includes contact information for the Investor Relations Department in Europe and the US but does not contain specific risk factors, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the actual release of the 2002 sales and results press releases on the scheduled dates of January 22 and February 18, 2003.
- Confirm the company's adherence to the disclosed 2003 reporting calendar for quarterly and semi-annual updates.
- Note that this filing contains no financial data; investors must refer to the upcoming 2002 results press release for performance metrics.